• 대한수의학회지
• /
• 제61권1호
• /
• pp.8.1-8.10
• /
• 2021

The purpose of this retrospective study was to describe cases of feline intermediateto high-grade alimentary lymphoma regarding signalment, clinical presentation, laboratory findings, response to therapy (modified 25-week University of Wisconsin-Madison [UW-25] vs. COP [cyclophosphamide, vincristine, prednisone]), toxicosis, and outcomes and to identify prognostic factors. Sixteen cats were treated with chemotherapy protocols. Response rates and survival did not differ statistically between the two protocols. The progression-free interval (PFI) and median survival time (MST) in cats achieving a response to therapy were longer than in those with no response [NR] (complete remission [CR] vs. partial remission [PR] vs. NR; PFI, 124 vs. 49 vs. 12 days, p < 0.001; MST, 361 vs. 118 vs. 16 days, p < 0.001). Clinical stage was another prognostic factor for PFI and MST. The PFI and MST in cats in stage I were longer than in those in other stages (PFI, 107 days vs. 30 days; MST, 193 days vs. 54 days). Hematologic and gastrointestinal toxicosis was mostly low grade. In comparing the modified UW-25 protocol with the COP protocol, there was not much difference in the number of neutropenic episodes and grade levels.

• Genomics & Informatics
• /
• 제14권4호
• /
• pp.205-210
• /
• 2016

Interleukin-10 (IL10) plays an important role in initiating and maintaining an appropriate immune response to non-Hodgkin lymphoma (NHL). Previous studies have revealed that the transcription of IL10 mRNA and its protein expression may be infl uenced by several single-nucleotide polymorphisms in the promoter and intron regions, including rs1800896, rs1800871, and rs1800872. However, the impact of polymorphisms of the IL10 gene on NHL prognosis has not been fully elucidated. Here, we investigated the association between IL10 polymorphisms and NHL prognosis. This study involved 112 NHL patients treated at the National Cancer Center, Korea. The median age was 57 years, and 70 patients (62.5%) were men. Clinical characteristics, including age, performance status, stage, and extra-nodal involvement, as well as cell lineage and International Prognostic Index (IPI), were evaluated. A total of four polymorphisms in IL10 with heterozygous alleles were analyzed for hazard ratios of overall survival (OS) and progression-free survival (PFS) using Cox proportional hazards regression analysis. Diffuse large B-cell lymphoma was the most common histologic type (n = 83), followed by T-cell lymphoma (n = 18), mantle cell lymphoma (n = 6), and others (n = 5). Cell lineage, IPI, and extra-nodal involvement were predictors of prognosis. In the additive genetic model results for each IL10 polymorphism, the rs1800871 and rs1800872 polymorphisms represented a marginal association with OS (p = 0.09 and p = 0.06) and PFS (p = 0.05 and p = 0.08) in B-cell lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). These findings suggest that IL10 polymorphisms might be prognostic indicators for patients with B-cell NHL treated with R-CHOP.

• Tuberculosis and Respiratory Diseases
• /
• 제43권4호
• /
• pp.651-656
• /
• 1996

저자 등은 입원 당시 전이성 암 또는 원발성 폐암의 방사선학적 소견을 보인 환자의 진단과정 중에 우리가 흔히 보는 형태가 아닌 유육종증 1예를 경험하여 문헌 고찰과 함께 보고하는 바이다.

• Journal of Yeungnam Medical Science
• /
• 제33권1호
• /
• pp.40-43
• /
• 2016

Retroperitoneal fibrosis (RF) is a disorder characterized by the presence of a retroperitoneal mass and concurrent systemic inflammation. Some cases of RF are recognized as belonging to the spectrum of immunoglobulin G4-related disease (IgG4-RD). Glucocorticoids are highly effective for treatment of retroperitoneal fibrosis, although the optimal dose and duration of therapy have not been established. An initial dose of prednisone (40-60 mg) daily is usually administered with a tapering scheme. We report on a 55-year-old man diagnosed with IgG4-related RF and successfully treated with a 3-day course of daily 250 mg (4 mg/kg) intravenous methylprednisolone, which resulted in the prompt resolution of urinary obstruction and systemic symptoms.

• Tuberculosis and Respiratory Diseases
• /
• 제53권4호
• /
• pp.463-469
• /
• 2002

저자들은 비폐색과 두통을 주소로 내원한 49세 남자에서 단백뇨 및 혈뇨와 병발된 다발성 폐결절을 발견하였고, c-ANCA와 조직검사를 통해 부비동, 폐, 신장을 침범한 Wegener씨 육아종증을 진단하고, cyclophosphamide와 스테로이드 병합투여로 증세가 호전되고, 흉부 방사선 사진에서도 호전된 소견을 보이는 환자를 경험하였기에 문헌고찰과 함께 보고하는 바이다.

• Asian Pacific Journal of Cancer Prevention
• /
• 제17권3호
• /
• pp.1513-1517
• /
• 2016

Background: A combination of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is one of the most effective front-line therapies to treat B-cell non-Hodgkin's lymphoma (NHL). The aim of this trial was to evaluate overall survival (OS), progression free survival (PFS) and toxicity of R-CHOP-14 compared to R-CHOP-21 in untreated stage III and IV B-cell NHL patients with Iranian ethnicity. Materials and Methods: In phase III trial, patients with previously untreated stage III and IV indolent and aggressive B-cell NHL were randomly assigned by using a minimization method to receive six to eight cycles of either R-CHOP-21 (administered every 21 days) or R-CHOP-14 (administered every 14 days with granulocyte colony-stimulating factor). Results: A total of 143 patients were randomly enrolled in our study (66 patients in R-CHOP-14 group and 77 patients in R-CHOP-21), between 2011 and 2014. The mean follow-up was 45 months at the time of treatment analysis. The 2-year and 5-year PFS rates for the R-CHOP-14 group were 83.6% vs 73.6% and for R-CHOP-21 group were 75% vs 54%. The 2-year and 5-year OS rates for R-CHOP-14 group were 98% vs 89% and for R-CHOP-21 group were 84.4% vs 67.5%. There was a significant correlation for PFS and OS in the two arms. There was no significant difference between adverse events with the two regimens. Conclusions: In our research improved survival was found with CHOP-14 as compared to CHOP-21. It is possible that drug metabolism in different races/ethnicities may be one important factor.

• Tuberculosis and Respiratory Diseases
• /
• 제62권6호
• /
• pp.540-544
• /
• 2007

폐농양의 치료 중에 발생하는 기질화 폐렴은 흔하게 관찰 되는 소견은 아니다. 기질화 폐렴은 특별한 원인 없이 발생하기도 하지만, 감염의 치료 과정에서 이차적 기질화 폐렴이 발생 할 수도 있다. 본 증례는 62세 남자 환자에서 폐농양을 치료하는 과정에서 발생한 기질화 폐렴을 경기관지 폐생검을 통해 확인하고 부신피질 호르몬을 투여로 효과적으로 치료한 예를 경험하였기에 보고하는 바이다.

• 한국임상약학회지
• /
• 제16권1호
• /
• pp.14-22
• /
• 2006

Purpose: To determine the short (1 year of transplant) and long-term (1-5 years of transplantation) risk factors affecting the graft and patient survival in kidney transplantation recipients. Methods: Records of 149 patients who received kidney transplantation in 1996 from Asan Medical Center were followed for 5 years retrospectively. Results: All patients initiated triple immunosuppressive therapy with cyclosporine, prednisone and azathioprine. One, two, three, four, five year patient and graft survival rates were 98.7%, 98.0%, 98.0%, 97.3%, 97.3%, and 96.6%, 95.2%, 94.6%, 92.5%, 91.8%, respectively. There were 30 cases of acute rejection (AR) and 6 cases of chronic rejection (CR) within $2.1{\pm}3.2$ months and $42.1{\pm}13.2$ months of transplantation, respectively. The risk factors for AR were donor's age older than 30 years (p=0.02) and cardiovascular disease (p=0.05). The risk factors for CR were AR (p=0.0169) and episode of complications (p=0.0330). Increasing period of dialysis (p=0.0473), episodes of AR (p<0.0001) and complication (p=0.0317) were significant factors for graft loss. Seven grafts were lost from noncompliance during 1-5 year period. The most com- mon cause of the graft loss for both periods was the graft rejection. The graft survival rate was significantly lower in patients with than without rejection episodes (77.4% vs. 90.0%, p=0.002). Conclusions: Survival rate of the graft with rejection was significantly lower. The risk factors affecting AR were donor's age older than 30years and CVD. AR and episode of complications within 1year were the risk factors for CR and graft loss.

• 한국미생물·생명공학회지
• /
• 제19권3호
• /
• pp.242-247
• /
• 1991

Arthrobacter simplex IAM 1660의 스테로이드 $\Delta^1$-dehydrogenase에 대한 각종 steroid의 유도조건과 효과를 검토하였다. 그 결과 시험한 스테로이드 중 hydrocortisone이 가장 큰 효과를 나타냈고 progesterone, prednisolone, prednisone, androstenstendione의 순으로 유도효과를 보였고, 스테롤에 의해서는 유도효과가 낮았다. 유도 스테로이드의 특성으로는 스테로이드 모핵 C-3위가 수산기인 것보다 캐톤기이며 C-4위에 이중결합이 존재하고 스테로이드 D고리의 측쇄가 짧은 것이 유도 효과가 높았다.

• 한국임상수의학회지
• /
• 제24권2호
• /
• pp.244-246
• /
• 2007

20 개월령의 알라스칸 말라뮤트 견에서 특발성 다발성근염의 임상증상과 병리학적 소견을 서술하였다. 임상 증상은 급성 허약을 동반한 진행성 운동불내성, 근 위축, 후지의 동시적 걸음걸이, 계란 위를 발끝으로 걷듯 짧고 경직된 걸음 등을 보였다. 신체검사와 임상검사에서는 신경계나 골격계 그리고 다른 질병과 관련된 이차적인 근 질환의 증거가 없었다. 그래서 가장 근 위축이 심한 부위에서 병리조직 검사를 위한 근 생검을 실시하였다. 골격근의 병리검사 결과 근 섬유의 괴사와 함께 단핵세포의 침윤이 관찰되어, 특발성 다발성근염으로 진단하였다. 초기치료는 통증경감과 보조치료를 시작하여 프레드니손 2 mg/kg를 경구로 매일 투여하는 면역억제 요법을 시행하였다. 3주 후 환자는 혈액, 혈청학적 검사에서 정상으로 회복될 뿐만 아니라 걸음걸이, 식욕, 운동의 향상을 나타냈다.